Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study

Silvia Nozza(IRCCS Ospedale San Raffaele), Adriano Lazzarin(Vita-Salute San Raffaele University), Marco Ripa(Vita-Salute San Raffaele University), Andrea Antinori(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Davide De Battista(Vita-Salute San Raffaele University), Mauro Malnati(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Manuela Pogliaghi(Hôpital Fernand-Widal), Stefania Chiappetta(Vita-Salute San Raffaele University), Sandrine Ottou(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Massimo Di Pietro(Ospedale SS. Annunziata), Stefano Bonora(Ospedale Amedeo di Savoia), Francesco Mazzotta(Ospedale SS. Annunziata), Mauro Zaccarelli(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani)
Clinical Microbiology and Infection
December 22, 2014
10.1016/j.cmi.2014.12.006
Cited by 26

Related Papers

Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620